tbuckley/cabot-search huggingface dataset:
A population-based analysis of overall survival associated with sunitinib given as intermittent, continuous, or nonconventional individualized dosing regimens for metastatic renal cell carcinoma.
Authors: Victoria Kletas, Winnie Cheng, Christian K. Kollmannsberger, Mario Law De Lemos, Sally Man
Journal: Journal of Clinical Oncology (2013)

e15541 Background: Standard dosing regimen of sunitinib for metastatic renal cell carcinoma (mRCC) consists of 4 weeks treatment followed by 2 weeks rest (intermittent dosing, ID). Alternative regimens have been suggested, including daily dosing regimen (continuous dosing, CD) and non-conventional dosing (non-conventional dosing: 2 weeks on / 1 week off, ND) to provide more individualized therapy with less toxicities. It is unclear whether non-standard sunitinib dosing affects survival outcomes. Methods: mRCC patients treated with sunitinib between July 1, 2007-2011 were identified from the British Columbia Cancer Agency (BCCA) pharmacy database, a publicly funded cancer care organization. Medical records and dispensing data were reviewed retrospectively to categorize sunitinib dosing as ID, CD or ND. Primary outcome was to compare overall survival (OS) associated with varying regimens, with secondary outcomes of progression free survival (PFS) and treatment discontinuation due to adverse effects (AE). Results: A total of 180 patients were identified. Heng prognostic risk criteria were assessable in 116 patients. Of these, 28 (24%), 62 (53%) and 26 (22%) had low-, intermediate- and high-risk disease. Most patients received ID (120, 67%), followed by CD (32,18%) and ND (28,16%). Compared to ID, CD was associated with similar OS (median 9 vs. 13 months, HR 0.67, 95% CI 0.43-1.06, p=0.088) while ND was associated with significantly longer OS (median 9 vs. 23 months, HR 0.55, 95% CI 0.34-0.90, p=0.016). PFS was significantly better for CD (median 4 vs. 9 months, HR 0.61, 95% CI 0.40-0.94, p=0.025) and ND (median 4 vs. 10 months, HR 0.61, 95% CI 0.39-0.95, p=0.03) when compared to ID. Similar to prior sunitinib trials, a significant proportion of patients (20%) discontinued sunitinib therapy due to AE. Conclusions: In comparison to the standard ID regimen, dosing sunitinib with alternative regimens may improve OS and PFS in patients with mRCC.
TRENDS AND IMPACT OF IMPLANTABLE CARDIOVERTER DEFIBRILLATOR IMPLANTATIONS IN PATIENTS WITH CARDIAC AMYLOIDOSIS: A 16-YEAR ANALYSIS
Authors: Ameesh Isath, Stuthi Perimbeti, Ashish Correa, Kamala Ramya Kallur, Bharat Narasimhan, Claire Huang Lucas, Subrat Das, Anwar Chahal, Deepak Padmanabhan, Davendra Mehta
Journal: Journal of the American College of Cardiology (2020)
CHARACTERIZATION OF THE PERI-AORTIC SUBSTRATE FOR VENTRICULAR TACHYCARDIA ABLATION: PROGNOSTIC VALUE OF MAGNETIC RESONANCE IMAGING
Authors: Takuro Nishimura, Michael Raiman, Dalise Shatz, Gaurav A. Upadhyay, Zaid Aziz, Andrew D. Beaser, Hemal M. Nayak, Roderick Tung
Journal: Journal of the American College of Cardiology (2020)
HEART FAILURE WITH REDUCED EJECTION FRACTION AND NOCTURNAL ATRIOVENTRICULAR BLOCK IN PATIENT WITH SLEEP APNEA HYPOPNEA SYNDROME
Authors: Weiwei Xie, Yuxi Li, Erdong Chen, Yang Yu, Ying Yang, Cheng Zhang, Yueyuan Li, Pengkang He, Wenhui Ding, Jianping Li, Xinan Cen
Journal: Journal of the American College of Cardiology (2020)
Pancreatic neuroendocrine tumors: Single institution review over 10 years.
Authors: Aakanksha Asija, Stacey Milan, Anthony Prestipino, Charles Yeo, Madhavan V. Pillai
Journal: Journal of Clinical Oncology (2013)

e15183 Background: Pancreatic neuroendocrine tumors(pNET) are rare tumors accounting for less than 5% of pancreatic cancer. They are functionally and biologically heterogeneous and have not been studied in great detail until recently. Methods: We conducted a retrospective review of 79 consecutive patients with pNET diagnosed and treated at Thomas Jefferson University Hospital between the years of 2000 and 2010. Results: Of the 79 patients whose records were reviewed, 32 were male and 47 were female. Median age at diagnosis was 61 years. Two cases were associated with MEN1 syndrome. Primary tumor arose in the head, body and tail of the pancreas in 15, 10 and 26 patients, resp. In 6 patients, the tumor was multifocal. The neuroendocrine tumor was accompanied by pancreatic adenocarcinoma in 1 patient and intraductal papillary mucinous neoplasm in 3. In 10 patients, distant metastasis was detected, involving liver only. Tumor was functional in 9 patients: 5 insulinoma, 2 gastrinoma,1 glucagonoma and 1 VIPoma. As per TNM staging, 28, 22 and 10 patients were Stage I, II and III, and IV at diagnosis. Treatment by surgical resection was undertaken in 54 patients. In 21 patients, the tumor was discovered incidentally; 21 patients presented with abdominal pain. Other symptoms were irregular bowel movements, weight loss and jaundice. 51 of the 79 (64.5%) patients were alive at last follow up. On univariate analysis, median survival for females was 137 months vs 114 months for male. Median survival for patients with functional tumors was similar to those with nonfunctioning tumors (118 and 115 months, resp). Median survival for patients with Stage I, II, and III and Stage IV patients were 234,112 and 40 months resp. Median survival for patients who underwent surgical resection was 130 months vs those who did not (30 months). Conclusions: Majority of pNET were located in the body and tail of pancreas; an area requiring thorough scrutiny with special imaging studies for diagnosis. Only a minority of patients presented with liver metastasis(12%) and a smaller number showed hormonal activity (11%). Prognosis improved markedly in patients who underwent surgical resection. Therefore, whenever appropriate, surgical resection should be the treatment of choice in patients with pNET.
Effect of phosphotidylinositol 3-kinase-delta inhibitor idelalisib (GS-1101) on signaling in primary non-Hodgkin lymphoma cells: Correlative studies from NCT01306643.
Authors: Adriana Arita, Katherine Hanlon, Halina Chkourko, Brian Joseph Lannutti, David Michael Johnson, Janice Lynn Gabrilove, Eileen Scigliano, Samir S. Parekh, Joshua Brody
Journal: Journal of Clinical Oncology (2013)

8579 Background: Studies of GS-1101, an oral phosphatidylinositol 3-kinase (PI3K)d-specific inhibitor, in heavily pre-treated patients with indolent-non-Hodgkin's lymphomas (iNHL) have shown marked clinical activity [Kahl BS, et al., Blood 2010]. We have shown that GS-1101 blocks both constitutive and inducible signaling events proximally downstream of PI3K [Lannutti BJ, et al., Blood 2011]. We hypothesized that flow-cytometric interrogation of PI3Kd-inhibition in iNHL samples might demonstrate signaling differences between patients that can be correlated with clinical outcomes. Methods: Single-cell suspensions of biopsy specimens from patients were incubated with or without GS-1101, B-cell receptor stimulated and stained with lineage markers and phospho-specific antibodies targeting signaling nodes proximally (e.g. pAkt S473) or distally (e.g. pS6 S235/6) downstream, or "parallel" to (e.g. pErk1/2) described PI3K pathways. Results: Healthy and iNHL B cells demonstrated complete or near-complete inhibition of PI3K proximal downstream signaling by GS-1101. PI3K distal downstream signaling was completely inhibited by GS-1101 in healthy B cells. The degree inhibition of distal downstream signaling was variable between iNHL patients. iNHL showed marked variability in the degree of PI3K distal downstream signaling amongst tumor cells within the same sample, suggesting an admixture of "PI3K-dependent“ and "PI3K-independent" tumor cells. We also observe variable PI3K-independence amongst other NHL histologies such as mantle cell lymphoma. Additionally, combining inhibition of PI3K with that of other signaling nodes shows additive distal downstream effects. Conclusions: We demonstrate that GS-1101 blocked both constitutive and invoked signaling proximally downstream of PI3K in primary iNHL cells. By correlating clinical outcomes in the ongoing study with signaling readouts between patients we may develop predictive rules for response. Ongoing studies will focus on studying the change in intratumoral cell subsets which develop in vivo as patients progress on PI3Kd inhibitor therapy.
68Ga–Prostate-Specific Membrane Antigen Uptake in Dissecting Abdominal Aortic Aneurysm
Authors: Veronica Chi Ken Wong, Joshua Wei Liang Yip, Amanda Stevanovic, Ken Le, Robert Mansberg
Journal: Clinical Nuclear Medicine (2020)

An 81-year-old man with prostate adenocarcinoma (Gleason 4 + 3 = 7) treated with brachytherapy and intermittent androgen deprivation therapy was referred for serial Ga-prostate-specific membrane antigen (PSMA-HBED-CC) PET/CT scans for rising prostate-specific antigen. Findings were suggestive of local prostatic recurrence and nodal metastases. An incidental PSMA-avid focus was noted in the anterior wall of an infrarenal aortic aneurysm, with a contrast-enhanced hyperdense region surrounded by a semilunar hypodense region anteriorly, consistent with enlarging dissecting thrombus. Increased PSMA avidity in atherosclerotic hypertensive lesions may relate to active plaque instability, indicating a need for further evaluation.
Parathyroidectomy and Hypertension
Authors: Sabba A. Hussain
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
DEVELOPMENT OF A DECISION AID FOR OLDER ADULTS WITH NON ST ELEVATION MYOCARDIAL INFARCTION
Authors: John A. Dodson, Jenny Summapund, Sohah N. Iqbal, Erica Sarah Spatz, Mallory Barnett, Rachel Sibley, Sarwat I. Chaudhry, Victoria V. Dickson, Daniel D. Matlock
Journal: Journal of the American College of Cardiology (2020)
Superselective intra-arterial chemotherapy for oral cancer by subcutaneous implantation of an intra-arterial catheter and an infusion reservoir: A new chemotherapy method to improve the quality of life and curative effect.
Authors: Masatoshi Ohmae, Iwai Tohnai, Itsuro Kato, Mitsuhiro Nakazawa
Journal: Journal of Clinical Oncology (2013)

6096 Background: We have developed a superselective intra-arterial chemotherapy (iaCT) approach for oral cancer, in which intra-arterial catheter is retrogradely inserted via the superficial temporal artery (STA) and/or occipital artery (OA). This approach increases chemotherapy efficiency but remarkably decreases activities of daily living (ADL) because the catheter penetrates the skin over the approaching artery (STA/OA). Methods: This study assessed our new outpatient iaCT approach involving implantation of an intra-arterial catheter connected to a subcutaneous infusion reservoir. We included 10 patients who had oral cancer treated using outpatient iaCT: tongue carcinoma, 7; cheek mucosal carcinoma, 1; upper gingival carcinoma, 1; palatal carcinoma, 1. In this approach, the STA or OA or both were percutaneously dissected out, a catheter was inserted, and the catheter tip was superselectively placed in the tumor-feeding artery. The extra-arterial catheter portion was implanted through a subcutaneous tunnel and was connected to a subcutaneous infusion reservoir implanted around the mastoid process. The patients were discharged after catheterization, and the chemotherapeutic agent was intra-arterially administered at the Outpatient Chemotherapy Center of Rinku General Medical Center once or twice a week. Intra-arterial infusion was repeated 6 times per course. Results: The response rate was 100%, i.e., 8 cases of CR and 2 of PR; patients with PR underwent surgery.Their ADLs were scarecely disturbed exept for ambulatory visits. Conclusions: In this approach, the catheter is completely implanted subcutaneously; therefore, usual catheter-related issues (e.g., infection, catheter fall out) rarely occur. Because this leads to very good ADLs, outpatient chemotherapy can be safely performed. Consequently, the quality of life (QOL) improves and medical expenses decrease.Our new outpatient iaCT approach improves QOL of and curative effects for oral cancer patients if the ambulatory convenience and the performance status are good.
Analysis of resilience scores in a cohort of solid tumors ambulatory cancer patients in chemotherapy treatment
Authors: A. F. Ferreira Filho, A. P. Wunder, D. L. da Silva, L. Slomka, M. W. Machado, M. P. dos Santos, S. Graeff, D. Freitas, A. Friedrich
Journal: Journal of Clinical Oncology (2009)

e20736 Background: Resillience is the ability to successfully cope with change or misfortune, allowing a person or a group to regain balance and keep going despite adversity and also to find meaning amidst confusion and tumult. It is a positive personality characteristic that enhances individual and group adaptation. Very scanty data exists regarding its quantification and distribution in cancer patients. The objective of this study is to evaluate and describe resilience scores in a population of ambulatory solid tumors cancer patients receiving chemotherapy treatment. Methods: Individual Resillience scores were measured by the Wagnild and Young Scale, validated for portuguese language from Brazil. It is composed by 25-item questions, scored on a 7-point scale from 1 = disagree, to 7 = agree, with all items worded positively. Possible scores range from 25 to 175 with higher scores reflecting higher resilience. During the year 2008, this scale was applied to 48 ambulatory solid tumor cancer patients in chemotherapy treatment at Oncosinos / Hospital Regina in Novo Hamburgo, Brazil. The study was approved by the Ethics comitte and all patiens signed the informed consent form. Results: The mean age of patients was 52 years (19–76) and 34 (70%) were women. The most common cancer types were: breast (48%), colo-rectal (21%) and prostate (8%). Most patients (47%) had stage IV disease and were in palliative chemotherapy treatment. Stage III cancer was present in 40% and stages I and II in 13% of patients. The mean score of resilience was 141+ 12 (101–174). The scores demosntrated a normal statistical distribution. No statistical differences in the mean resillience scores were detected between groups of patients as defined by: sex (P=0.11), age &gt; or &lt; 50 years (P=0.9), cancer type (P= 0.78), disease staging (P= 0.9), or the chemotherapy treatment intention, if palliative or curative (P=0.91). Conclusions: The resilience scores in this cohort of patients display a statistically normal distribution. Our results suggest that the total resillience score is an intrinsic individual characteristic that is independent of cancer stage, cancer type, age and sex of the patients. Further research is necessary to clarify the implications of these findings. No significant financial relationships to disclose.
PROTEIN EXPRESSION PROFILING OF PULMONARY VEINS AND ARTERIES IN EXPERIMENTAL PULMONARY VENOUS HYPERTENSION AS A MODEL OF GROUP 2 PH
Authors: Ahmed Fayyaz, Michael Sabbah, Surendra Dasari, Leigh Griffiths, Sarah Jenkins, Barry Borlaug, William Edwards, Margaret M. Redfield
Journal: Journal of the American College of Cardiology (2020)
Prognostic significance of metastatic cascade in melanoma.
Authors: Travis Brad Kidner, Jeong Lim Yoon, Mark B. Faries, Donald L. Morton
Journal: Journal of Clinical Oncology (2012)

e19029 Background: The ability of metastases to spawn subsequent generations of metastatic lesions is controversial, and its prognostic significance is unknown. We hypothesize that melanoma metastases that have spread to draining lymph nodes will have a worse prognosis than those that have not. Methods: One hundred consecutive patients who had undergone pulmonary resection for metastatic melanoma and who had concomitant hilar and/or mediastinal lymph node evaluation available were identified. Patient demographics, tumor characteristics, mediastinal lymph node status, and overall survival were analyzed. Results: 100 patients (71%) were male and the mean age at metastasectomy was 55 years (mean age at diagnosis 47 years.) The average Breslow thickness was 2.43mm (range 0.46 – 20.55). Twenty-one (21%) of the patients had evidence of metastatic disease present in regional lymph nodes during pulmonary resection. The 5-year overall survival for patients with positive mediastinal lymph nodes was 16% versus 36% with node negative disease (p=0.0005). On multivariate analysis, age at pulmonary resection (HR 1.018, 95% CI 1.002-1.035) and regional lymph nodes status (HR 3.203, 95% CI 1.774-5.781) were found to be independent prognostic indicators of 5-year overall survival. Conclusions: Regional lymph node status is an important prognostic factor in patients with pulmonary metastatic melanoma, and regional nodal assessment should be considered during metastasectomy. The metastatic cascade appears to be a strong prognostic factor in melanoma.
Rising Emergency Department Visits for Suicidal Ideation and Self-harm
Authors: Bridget M. Kuehn
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
COMPARISON OF SIX-MONTHS OUTCOMES IN PATIENTS BRIDGED TO HEART TRANSPLANT (HT) WITH INOTROPES BEFORE AND AFTER UNOS HEART ALLOCATION POLICY CHANGE
Authors: Grace Liu, Eugene Christopher DePasquale, Joseph Rahman, Kruti Pandya, Darko Vucicevic, Aaron Wolfson, Jonathan Nattiv, Robin Chand, Pooya Banankhah, Percy Genyk, Philip Kingsford, Jason Li, Ajay Vaidya
Journal: Journal of the American College of Cardiology (2020)
HEART-TYPE FATTY ACID BINDING PROTEIN RATHER THAN TROPONIN I ASSOCIATES WITH INCREASED RISK OF MYOCARDIAL INJURY AND ADVERSE EVENTS IN PATIENTS RECEIVING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
Authors: Hui-Wen Zhang, Jing-Lu Jin, Ye-Xuan Cao, Hui-Hui Liu, Yuan-Lin Guo, Na-Qiong Wu, Cheng-Gang Zhu, Ying Gao, Rui-Xia Xu, Qian Dong, Jing Sun, Jian-Jun Li
Journal: Journal of the American College of Cardiology (2020)
DIFFERENCES IN QUALITY OF LIFE AND FUNCTIONAL STATUS OF PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY, ACCORDING TO SEX
Authors: Evangelos Oikonomou, Andreas Angelopoulos, Georgia Vogiatzi, George Lazaros, Alexios Antonopoulos, Antigoni Miliou, Paraskevi Papanikolaou, Vasiliki-Chara Mystakidi, Panagiotis Theofilis, Christos Georgakopoulos, Evangelia Sigala, Charalambos Vlachopoulos, Dimitris Tousoulis
Journal: Journal of the American College of Cardiology (2020)
LEFT VENTRICULAR GLOBAL LONGITUDINAL STRAIN PREDICTS RISK IN PATIENTS WITH MIXED AORTIC VALVE DISEASE: EVIDENCE FOR A CUT-OFF POINT
Authors: Yoshihito Saijo, Nicolas Isaza, Julijana Z. Conic, Douglas Johnston, Eric Roselli, Milind Y. Desai, Richard A. Grimm, Lars G. Svensson, Brian P. Griffin, Zoran B. Popovic
Journal: Journal of the American College of Cardiology (2020)
Combination chemotherapy of intermittent erlotinib with pemetrexed for pretreated patients with advanced non-small cell lung cancer: A phase I dose-finding study.
Authors: Ryo Takahashi, Seigo Minami, Takashi Kijima, Hiroshi Kida, Takeshi Nakatani, Masanari Hamaguchi, Yoshiko Takeuchi, Izumi Nagatomo, Suguru Yamamoto, Isao Tachibana, Kiyoshi Komuta, Ichiro Kawase
Journal: Journal of Clinical Oncology (2012)

e18056 Background: Erlotinib and pemetrexed have been approved in second-line treatment for non-small cell lung cancer (NSCLC) and have different mechanisms of action. Their combination could potentially augment the antitumor activity brought by either agent alone. We investigated the safety in combination of erlotinib and pemetrexed in pretreated NSCLC patients. Methods: A phase I dose-finding study was performed in patients with stage III/IV nonsquamous NSCLC whose disease had progressed on or after receiving first-line chemotherapy. This study was registered as UMIN000002900. Patients received 500 mg/m 2 of pemetrexed intravenously every 21 days and erlotinib (100 mg in Level 1, 150 mg in Level 2) orally on days 2-16. Results: Twelve patients were recruited. Patient characteristics included median age of 66 (range, 48-78), 9 males, 9 stage IV, 7 adenocarcinoma, and 2 activating mutation-positives in the gene of epidermal growth factor receptor. Treatment was well-tolerated and the recommended dose of erlotinib was fixed on 150 mg. Dose-limiting toxicities were experienced in 3 patients: grade 3 elevation of serum alanine aminotransferase, repetitive grade 4 neutropenia that required the second dose reduction of pemetrexed, and grade 3 diarrhea. None experienced drug-induced interstitial lung disease. Three patients achieved partial response and 5 kept stable disease. Conclusions: Combination chemotherapy of intermittent erlotinib with pemetrexed was well-tolerated with promising efficacy against pretreated advanced nonsquamous NSCLC.
Intestinal Organoids: A Tool for Modelling Diet–Microbiome–Host Interactions
Authors: Josep Rubert, Pawel J. Schweiger, Fulvio Mattivi, Kieran Tuohy, Kim B. Jensen, Andrea Lunardi
Journal: Trends in Endocrinology and Metabolism (2020)

Dietary patterns, microbiome dysbiosis, and gut microbial metabolites (GMMs) have a pivotal role in the homeostasis of intestinal epithelial cells and in disease progression, such as that of colorectal cancer (CRC). Although GMMs and microorganisms have crucial roles in many biological activities, models for deciphering diet-microbiome-host relationships are largely limited to animal models. Thus, intestinal organoids (IOs) have provided unprecedented opportunities for the generation of in vitro platforms with the sufficient level of complexity to model physiological and pathological diet-microbiome-host conditions. Overall, IO responses to GMM metabolites and microorganisms can provide new insights into the mechanisms by which those agents may prevent or trigger diseases, significantly extending our knowledge of diet-microbiome-host interactions.